Drug Trial Radar · NCT05883449
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
25
Actual
Start
Oct 10, 2023
Primary completion
Nov 7, 2024
Study completion Jun 13, 2025
Sponsor
- Lead sponsor
- Affimed GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Artiva Biotherapeutics, Inc.
- First posted
- Jun 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Conditions
- Relapsed or Refractory Hodgkin Lymphoma
- Peripheral T Cell Lymphoma
Interventions
AFM13Drug
anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion
AB-101Drug
NK cell therapy, intravenous infusion
CyclophosphamideDrug
Lymphodepleting chemotherapy, intravenous infusion
FludarabineDrug
Lymphodepleting chemotherapy, intravenous infusion
Interleukin-2Drug
Immune cytokine, subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by Independent Radiology CommitteeTime frame: Disease assessments were conducted on Day 43 (+- 3 days) of each cycle. All subjects were treated for a maximum of 3 cycles.
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
O'Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama
City of Hope National Medical Center
Duarte, California
UC Irvine Health
Orange, California
Sarah Cannon Research Institute
Denver, Colorado
Norton Cancer Institute
Louisville, Kentucky
Beth Israel Deaconess Medical
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
John Theurer Cancer Center
Hackensack, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
UNC Immunotherapy Team, University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Cleveland Clinic
Cleveland, Ohio
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.